[PRESS RELEASE] – BLOOMFIELD HILLS, Mich., March 31, 2026 – Vlasic Labs announced that its CBD product line meets the current qualifications outlined in the Centers for Medicare & Medicaid Services (CMS) pilot program, a first-of-its-kind initiative allowing participating health care organizations to provide eligible hemp-derived products to Medicare beneficiaries.
This milestone represents a significant step forward in legitimizing CBD as part of mainstream medical care, reinforcing the role of nonintoxicating cannabinoids in patient-centered treatment models. Under the CMS program, eligible hemp products must meet strict federal standards for safety, dosing and THC content, further elevating the importance of quality and compliance across the category.
"For years, Vlasic Labs has been committed to producing high-quality, nonintoxicating CBD products formulated with consistency, rigorous testing and transparency," Vlasic Lab CEO Willy Vlasic said. "As the hemp industry has evolved, we've remained focused on building a brand that prioritizes long-term trust over short-term trends. Meeting CMS's recently released standards reinforces that commitment, and we look forward to partnering with model participants to help expand access to reliable cannabinoid products for Medicare patients."
The hemp market has expanded rapidly in recent years, moving beyond CBD into a wide range of categories. Amid that growth, Vlasic Labs has maintained a clear and disciplined strategy, focusing on nonintoxicating formulations that align with medical use cases, regulatory stability and trusted distribution channels.
As health care providers participating in CMS models begin offering these products to patients starting April 2026, Vlasic Labs will work alongside participating organizations to support program implementation and deliver high-quality products that continue to meet all regulatory requirements as the program evolves.
